Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children

  • Read more about Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children

Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic

  • Read more about Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic

One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting

  • Read more about One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting

COVID-19 Hub

  • Read more about COVID-19 Hub

The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families

  • Read more about The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families

The Psychological Impact of the COVID-19 on Students.

  • Read more about The Psychological Impact of the COVID-19 on Students.

The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients

  • Read more about The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

  • Read more about Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

  • Read more about Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer

  • Read more about Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 256
  • Page 257
  • Page 258
  • Page 259
  • Current page 260
  • Page 261
  • Page 262
  • Page 263
  • Page 264
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA